These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 17605900)

  • 21. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series.
    Saperstein DA; Rosenfeld PJ; Bressler NM; Rosa RH; Sickenberg M; Sternberg P; Aaberg TM; Aaberg TM; Reaves TA;
    Ophthalmology; 2002 Aug; 109(8):1499-505. PubMed ID: 12153802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
    Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
    Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photodynamic therapy with verteporfin for age-related macular degeneration. American Academy of Ophthalmology.
    Ophthalmology; 2000 Dec; 107(12):2314-7. PubMed ID: 11186878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
    Blumenkranz MS; Bressler NM; Bressler SB; Donati G; Fish GE; Haynes LA; Lewis H; Miller JW; Monés JM; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Schachat AP; Schmidt-Erfurth U; Sickenburg M; Singerman LJ; Slakter JS; Strong A; Vannier S;
    Arch Ophthalmol; 2002 Oct; 120(10):1307-14. PubMed ID: 12365909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study.
    Rosenfeld PJ; Saperstein DA; Bressler NM; Reaves TA; Sickenberg M; Rosa RH; Sternberg P; Aaberg TM; Aaberg TM;
    Ophthalmology; 2004 Sep; 111(9):1725-33. PubMed ID: 15350329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4.
    Azab M; Benchaboune M; Blinder KJ; Bressler NM; Bressler SB; Gragoudas ES; Fish GE; Hao Y; Haynes L; Lim JI; Menchini U; Miller JW; Mones J; Potter MJ; Reaves A; Rosenfeld PJ; Strong A; Su XY; Slakter JS; Schmidt-Erfurth U; Sorenson JA; ;
    Retina; 2004 Feb; 24(1):1-12. PubMed ID: 15076937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration.
    Arias L; Pujol O; Berniell J; Rubio M; Roca G; Castillo L; Acebes E
    Br J Ophthalmol; 2005 Mar; 89(3):312-5. PubMed ID: 15722311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.
    Browning AC; Chung AK; Ghanchi F; Harding SP; Musadiq M; Talks SJ; Yang YC; Amoaku WM;
    Ophthalmology; 2005 Jul; 112(7):1227-31. PubMed ID: 15921757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.
    Keam SJ; Scott LJ; Curran MP
    Drugs; 2003; 63(22):2521-54. PubMed ID: 14609361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
    Ladd BS; Solomon SD; Bressler NM; Bressler SB
    Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Pieramici DJ; Bressler SB; Koester JM; Bressler NM
    Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration: results of an effectiveness study.
    Sharma S; Bakal J; Oliver-Fernandez A; Blair J
    Arch Ophthalmol; 2004 Jun; 122(6):853-6. PubMed ID: 15197060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodynamic therapy with verteporfin in Belgian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Mori R; Kelkar A; De Laey JJ
    Bull Soc Belge Ophtalmol; 2006; (299):57-64. PubMed ID: 16681088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
    Augustin AJ; Schmidt-Erfurth U
    Ophthalmology; 2006 Jan; 113(1):14-22. PubMed ID: 16360209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study.
    Soubrane G; Harding SP; Wolf S; Weichselberger A
    Eye (Lond); 2009 Apr; 23(4):791-800. PubMed ID: 18583995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.